{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T11:55:59Z","timestamp":1712663759500},"reference-count":23,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1536\/ihj.15-007","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T18:03:46Z","timestamp":1434564226000},"page":"471-473","source":"Crossref","is-referenced-by-count":1,"title":["Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect"],"prefix":"10.1536","volume":"56","author":[{"given":"Hironori","family":"Muraoka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisataka","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Porres-Aguilar M, Mukherjee D. Portopulmonary hypertension: an update. Respirology 2015; 20: 235-42.","DOI":"10.1111\/resp.12455"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Roberts KE, Fallon MB, Krowka MJ, <i>et al<\/i>. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest 2009; 135: 1470-5.","DOI":"10.1378\/chest.08-1909"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Roberts KE, Fallon MB, Krowka MJ, <i>et al<\/i>. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835-42.","DOI":"10.1164\/rccm.200809-1472OC"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Pellicelli AM, Barbaro G, Puoti C, <i>et al<\/i>. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology 2010; 61: 802-6.","DOI":"10.1177\/0003319710369101"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rubin LJ. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci 2012; 91: 517-21. (Review)","DOI":"10.1016\/j.lfs.2012.07.033"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 2007; 28: 117-25. (Review)","DOI":"10.1016\/j.ccm.2006.11.002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Imamura T, Kinugawa K, Hatano M, <i>et al<\/i>. Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device. J Artif Organs 2013; 16: 101-4.","DOI":"10.1007\/s10047-012-0662-4"},{"key":"8","unstructured":"8. Eriksson C, Gustavsson A, Kronvall T, Tysk C. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis 2011; 20: 77-80. (Review)"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011; 139: 109-14.","DOI":"10.1378\/chest.10-0574"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Imamura T, Kinugawa K, Nitta D, <i>et al<\/i>. Is the internal jugular vein or femoral vein a better approach site for endomyocardial biopsy in heart transplant recipients? Int Heart J 2015; 56: 67-72.","DOI":"10.1536\/ihj.14-156"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Imamura T, Kinugawa K, Murasawa T, <i>et al<\/i>. Cardiac allograft vasculopathy can be distinguished from donor-transmitted coronary atherosclerosis by optical coherence tomography imaging in a heart transplantation recipient: double layered intimal thickness. Int Heart J 2014; 55: 178-80.","DOI":"10.1536\/ihj.13-279"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Devaraj A, Loveridge R, Bosanac D, <i>et al<\/i>. Portopulmonary hypertension: improved detection using CT and echocardiography in combination. Eur Radiol 2014; 24: 2385-93.","DOI":"10.1007\/s00330-014-3289-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ghofrani HA, Humbert M. The role of combination therapy in managing pulmonary arterial hypertension. Eur Respiratory Rev 2014; 23: 469-75.","DOI":"10.1183\/09059180.00007314"},{"key":"14","unstructured":"14. Villa G, Morano R, Rom\u00e1n A, Gil J. Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension. Farm Hosp 2013; 37: 358-65. (Spanish)"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Imamura T, Kinugawa K, Hatano M, <i>et al<\/i>. Acute pulmonary vasoreactivity test with sildenafil or nitric monoxide before left ventricular assist device implantation. J Artif Organs 2013; 16: 389-92.","DOI":"10.1007\/s10047-013-0706-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Savale L, Magnier R, Le Pavec J, <i>et al<\/i>. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2013; 41: 96-103.","DOI":"10.1183\/09031936.00117511"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-44.","DOI":"10.1183\/09031936.00138706"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Vizza CD, Fedele F, Pezzuto B, Rubin LJ. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf 2012; 11: 1003-11.","DOI":"10.1517\/14740338.2012.714770"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gali\u00e9 N, Badesch D, Oudiz R, <i>et al<\/i>. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-35.","DOI":"10.1016\/j.jacc.2005.04.050"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Venitz J, Zack J, Gillies H, Allard M, Regnault J, Dufton C. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol 2012; 52: 1784-805. (Review)","DOI":"10.1177\/0091270011423662"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Rapoport RM, Zuccarello M. Endothelin(A)-endothelin(B) receptor cross talk in endothelin-1-induced contraction of smooth muscle. J Cardiovasc Pharmacol 2012; 60: 483-94. (Review)","DOI":"10.1097\/FJC.0b013e31826f32c1"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Yokoyama Y, Osano A, Hayashi H, <i>et al<\/i>. Endothelin-1 receptors in rat tissues: characterization by bosentan, ambrisentan and CI-1020. Biol Pharm Bull 2014; 37: 461-5.","DOI":"10.1248\/bpb.b13-00881"},{"key":"23","unstructured":"23. Kholdani CA, Fares WH, Trow TK. Macitentan for the treatment of pulmonary arterial hypertension. Vasc Health Risk Manag 2014; 10: 665-73."}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T09:56:53Z","timestamp":1498211813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/56\/4\/56_15-007\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.15-007","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}